Lori Westendorf

发表

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics

J. Petroziello, A. Wahl, C. Cerveny, 2005, Leukemia.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

I. Bernstein, P. Burke, R. Walter, 2013, Blood.

Development of orally active inhibitors of protein and cellular fucosylation

P. Burke, D. Benjamin, P. Senter, 2013, Proceedings of the National Academy of Sciences.

Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates

D. Benjamin, M. Jonas, C. Law, 2017, Molecular Cancer Therapeutics.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

John F. Valliere-Douglass, T. Lewis, Sa A. Wang, 2017, Molecular Cancer Therapeutics.

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

Jennifer B. Webster, Stephen C Alley, P. Carter, 2006, Protein engineering, design & selection : PEDS.

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

P. Carter, D. Benjamin, S. Alley, 2018, Protein engineering, design & selection : PEDS.

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

Robert Lyon, Charlotte F. McDonagh, Martha Anderson, 2008, Molecular Cancer Therapeutics.

Anti-CD30 diabody-drug conjugates with potent antitumor activity

P. Carter, H. Gerber, S. Alley, 2008, Molecular Cancer Therapeutics.

Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies

Damon L. Meyer, P. Carter, H. Gerber, 2007 .

SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

A. Nesterova, D. Benjamin, Leia M. Smith, 2014, Molecular Cancer Therapeutics.

A major role for zygotic hunchback in patterning the Nasonia embryo

Samuel D. Gale, S. Small, C. Desplan, 2005, Development.

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

A. Nesterova, T. Lewis, N. Okeley, 2023, Molecular cancer therapeutics.

Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction

D. Benjamin, J. Hunter, Fu Li, 2019, Molecular Cancer Therapeutics.

Abstract 3962: SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.

A. Nesterova, Leia M. Smith, D. Sussman, 2013 .